In this review, we discuss the recent development of molecular targeting drugs for RTK aberrations in cancers, including potential or established molecular targets of EGFR, HER2, ALK, ROS1, vascular endothelial growth factor receptor (VEGF(R)), MET, insulin-like growth factor 1 receptor (IGF1R) and fibroblast growth factor receptor (FGFR), focusing on therapies for individual patients with cancer. Here, ERBB2 is linked to cancer.